Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals
Macarthur Charles, Francine Noel, Paul Leger, Patrice Severe, Cynthia Riviere, Carole Anne Beauharnais, Erica Miller, John Rutledge, Heejung Bang, Wesley Shealey, Richard T D’Aquila, Roy M Gulick, Warren D Johnson, Peter F Wright, Jean William Pape & Daniel W Fitzgerald
Volume 86, Number 12, December 2008, 970-977
Table 2. Resistance mutations in Haitian patients 13–25 years of age with plasma HIV-1 RNA concentrations > 1000 copies/ml 12 months after initiation of ART, 2003–2005
| HIV-1 mutationa | Patients (n = 29) No. (%) |
|---|---|
| Any mutation conferring drug resistance | 25 (86) |
| Mutation conferring resistance to NNRTIb | 23 (79) |
| Reverse transcriptase M184V mutation conferring resistance to lamivudine | 21 (72) |
| Mutations conferring resistance to both NNRTI and lamivudine | 21 (72) |
| Mutations other than M184V conferring resistance to NRTIs | 11 (38) |
| Any thymidine analogue mutationc | 9 (31) |
| Two or more thymidine analogue mutations | 7 (24) |
| Mutations conferring resistance to lamivudine, other NRTIs and NNRTIs | 10 (35) |
ART, antiretroviral therapy; NNRTIs, non-nucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; RNA, ribonucleic acid.
a Based on International AIDS Society-USA guidelines.
20
b The most common NNRTI mutations were located in reverse transcriptase codons 103 and 181.
c Thymidine analogue mutations were located in reverse transcriptase codons 41, 67, 70, 210, 215 and 219.